

When citing an abstract from the 2019 annual meeting, please use the format below.

[Authors]. [Abstract Title]. Program No. XXX.XX. 2019 Neuroscience Meeting Planner.  
San Diego, CA: Society for Neuroscience, 2019. Online.

2019 Copyright by the Society for Neuroscience all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.

## **Basic-Translational-Clinical Roundtables**

### **262. Mechanisms of Drug Addiction: A Translational Perspective**

**Location:** Room N230B

**Time:** Monday, October 21, 2019, 8:30 AM - 11:00 AM

**Description:** This roundtable will focus on translatability of basic research in animals to human research in addiction in order not only to understand neurobehavioral mechanisms of addiction, but also to define new strategies for discovery of clinical treatments, especially regarding the current opioid crisis. Topics to be discussed include the neural systems underlying addiction, neuronal adaptations occurring within those systems, how different drugs of abuse produce addiction, and the role of aberrant learning and vulnerabilities in the drive to addiction.

**Organizer/Moderator:** \***T. W. ROBBINS;**  
Univ. of Cambridge, Cambridge, United Kingdom

**Disclosure: T.W. Robbins:** University of Cambridge full time, Wellcome Trust Investigator Award, MRC Programme Grant, Shionogi Inc project grant, Royalties for CANTAB (Cambridge Cognition), Cambridge Cognition, Unilever, Greenfields Inc, Cassava Inc, Editorial honoraria Elsevier and Springer Nature.

**Speaker: R. Goldstein;**  
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.

**Disclosure: R. Goldstein;** None.

**Speaker: R. Sinha;**  
Yale Univ Sch Med, NEW HAVEN, CT.

**Disclosure: R. Sinha:** None.

**Speaker: A. Bechara;**  
Dept. of Psychology, University of Southern California, Los Angeles, CA.

**Disclosure: A. Bechara:** None.

## **Basic-Translational-Clinical Roundtables**

### **441. Exoskeletons and Robotics for Neurorehabilitation**

**Location:** Room N230B

**Time:** Tuesday, October 22, 2019, 8:30 AM - 11:00 AM

**Description:** This session will include a state-of-the-art overview of the use of robotics and exoskeletons in populations with neurological impairments. Specific presentations will include upper body robotic interventions for functional and neurological gains, robotic interventions for children with neurological impairments, and lower extremity exoskeletons for over ground ambulation. The lower extremity exoskeletal-assisted walking data will be presented from a randomized, controlled clinical trial.

**Organizer/Moderator: A. M. SPUNGEN;**  
Icahn Sch. of Med. at Mount Sinai, New York, NY

**Disclosure: A. M. Spungen:** None.

**Speaker: S. Agrawal;**  
Columbia University, New York, NY.

**Disclosure: S. Agrawal:** None.

**Speaker: N. Hogan;**  
MIT, Cambridge, MA.

**Disclosure: N. Hogan:** E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); I own stock in Bionik Laboratories, which manufactures technology for robot-aided neuro-rehabilitation. F. Consulting Fees (e.g., advisory boards); I am a member of the scientific advisory board of Bionik Laboratories.

**Speaker: C. Walsh;**  
Harvard School of Engineering and Applied Sciences, Cambridge, MA.

**Disclosure: C. Walsh:** None.

## **Basic-Translational-Clinical Roundtables**

### **624. Gene Therapy in Neurological Diseases**

**Location:** Room N230B

**Time:** Wednesday, October 23, 2019, 8:30 AM - 11:00 AM

**Description:** Gene therapy has advanced rapidly in the past five years, with technological advances and encouraging early clinical studies. This roundtable will focus on the opportunities and challenges as the field progresses, with a focus on the development of disease-modifying therapies that address urgent unmet needs of patients with neurological disorders. Discussion topics will include: technologies that are driving the field, with a focus on AAV platforms; leveraging advances in neurogenetics to identify validated therapeutic targets and patient subpopulations; rare monogenic disorders and clinical therapeutic strategies; the pursuit of gene

therapy approaches for genetically complex disorders; and CNS region- and cell-selective approaches.

**Organizer/Moderator: \*A. ABELIOVICH;**

Pathol, Neurol, Cnt Neurobio & Behav, Prevail Therapeut., New york, NY

**Disclosure: A. Abeliovich:** Prevail Therapeutics, Prevail Therapeutics, Alector.

**Speaker: B. L. Davidson;**

Children's Hospital of Pennsylvania, Pennsylvania, PA.

**Disclosure: B.L. Davidson:** B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; PI on NIH Research Grants, Co-investigator on NIH Research Grants, PI, CF Foundation Grant, PI, Sponsored Research, Sanofi Aventis, PI, Sponsored Research, National Ataxia Fdn., PI, Sponsored Research, United MSD Fnd., PI, Sponsored Research, Spark Therapeutics (pending), PI, Sponsored Research, Prevail Therapeutics (Pending), PI, Sponsored Research, Intellia Therapeutics (Pending), PI, Sponsored Research, Navitor Pharm, PI, Sponsored Research, Homology Medicines. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Spark Therapeutics, co-founder, Talee Bio, co-founder. F. Consulting Fees (e.g., advisory boards); Scientific Advisory Board, Intellia Therapeutics, Scientific Advisory Board, Sarepta Therapeutics, Scientific Advisory Board, Prevail Therapeutics, Scientific Advisory Board, Axovant, Scientific Advisory Board, Homology Medicines, Scientific Advisory Board, Panorama Medicine, Scientific Advisory Board, BrainNeu Bio (pending).

**Speaker: O. Danos;**

RegenX Bio, Washington, DC.

**Disclosure: O. Danos:** None.

**Speaker: P. Kaufmann;**

Society for Neuroscience, Washington, DC.

**Disclosure: P. Kaufmann:** None.

## **Dual Perspectives**

### **349: Dual Perspectives Session: Does Adult Neurogenesis Occur in the Human Brain?**

**Location:** Room S406B

**Time:** Monday, October 21, 2019, 1:00 PM - 2:00 PM

**Description:** Whether neurogenesis continues in the adult human brain has been contested for decades. Adult neurogenesis is a fascinating phenomenon involving the birth, migration and functional integration of a new neuron into established neural networks. In this Dual Perspectives session, Dr. Llorens-Martín will present recent evidence supporting and Dr. Alvarez-Buylla will present recent evidence questioning the presence of new neurons in the adult human hippocampus.

**Organizer/Moderator: A. J. EISCH**

Children's Hosp. of Philadelphia Res. Ctr., Philadelphia, PA

**Disclosure:**

**Speaker: A. Alvarez-Buylla**

Dept Neurosurgery, UCSF, San Francisco, CA.

**Disclosure:**

**Speaker: M. Llorens-Martín**

Universidad Autonoma De Madrid, Madrid, SPAIN.

**Disclosure:**

## **Storytelling**

### **182. The Storytelling Brain: How Neuroscience Stories Help Bridge the Gap Between Research and Society**

**Location:** Room S406B

**Time:** Sunday, October 20, 2019, 1:30 PM - 4:00 PM

**Description:** This storytelling session brings together neuroscientific discovery, science reporting, and personal storytelling in a synergetic and memorable way. Broad-appeal lectures will interweave with personal stories to showcase the effective ways in which neuroscience researchers and journalists can collaborate, how storytelling provides a common ground between science and art, and the power of narrative to hold captive our storytelling brains.

**Grant Support:** Netherlands Organization for Scientific Research (NWO) [Grant Number Vidi-276-89-007 to R.M. Willems]

**Chair: S. Martinez-Conde;**

Department of Ophthalmology, State University of New York Downstate Medical Center, Brooklyn, NY.

**Disclosure: S. Martinez-Conde:** None.

**182.01.** Introduction

**182.02.** The poisoner's guide to storytelling

**Speaker: D. Blum;**

Knight Science Journalism Program, Massachusetts Institute of Technology, Cambridge, MA.

**Disclosure: D. Blum:** None.

**182.03.** What my amnesia experience taught me about my memory research

**Speaker: G. J. Quirk;**

Psychiatry and Anatomy & Neurobiology, Univ Puerto Rico School of Medicine, San Juan, PUERTO RICO.

**Disclosure: G.J. Quirk:** None.

**182.04.** Mental simulation of fictional worlds during narrative comprehension

**Speaker: R. Willems;**

Centre for Language Studies, Radboud University, Nijmegen, NETHERLANDS.

**Disclosure: R. Willems:** None.

**182.05.** A new perspective on autism from a lifelong expert

**Speaker: N. Britton;**

Behavioral Sciences, Bunker Hill Community College, Boston, MA.

**Disclosure: N. Britton:** None.

**182.06.** The neuroscientist who lost her mind: my tale of madness and recovery

**Speaker: B. K. Lipska;**

Human Brain Collection Core, NIH/NIMH, Bethesda, MD.

**Disclosure: B.K. Lipska:** None.

**182.07.** The magic of storytelling

**Speaker: J. I. Swiss;**

N/A, N/A, San Diego, CA.

**Disclosure: J.I. Swiss:** None.

**182.08.** Closing Remarks